Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Ovintiv Inc. (DE) (OVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Ovintiv Inc. (DE) — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Ovintiv Inc. (DE) trades at $66.75 (market cap $18.44B). The key difference: Ovintiv Inc. (DE) is far larger — about 2.1× Kymera Therapeutics Inc. Common Stock's market cap, and Ovintiv Inc. (DE) pays a 1.8% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Ovintiv Inc. (DE) for 6 Days on average.
| KYMR | OVV | |
|---|---|---|
Market Cap | $8.87B | $18.44B |
Volume | 779,107 | 3,495,725 |
Sector | Health | Energy |
52-Week High | $127.31 | $66.97 |
52-Week Low | $55.80 | $35.97 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $22.77B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OVV trades at $66.66, up 2.36% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing robust revenue growth. Recent news highlights expansion in Permian and Montney assets, share buybacks, and strong free cash flow generation, positioning the stock for potential upside.
The outlook for OVV is positive, driven by operational strength and strategic acquisitions, though risks include commodity price volatility and natural gas headwinds. With a consensus price target of $76.00 and no sell ratings, Wall Street sentiment remains bullish, offering a favorable risk-reward profile for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Ovintiv Inc. (DE)
Ovintiv explores for and produces oil and natural gas in North America. Its operations are concentrated in major U.S. and Canadian resource basins.
Read more on OVV →
